Onychomycosis Treatment Guidelines

Introduction to Onychomycosis Treatment

The British Journal of Dermatology recommends terbinafine 250 mg daily as the best first-line treatment for dermatophyte onychomycosis, given for 6 weeks for fingernails and 12 weeks for toenails, due to its superior efficacy and similar safety profiles compared to other oral antifungals 1, 2, 3

For dermatophyte onychomycosis, the first-line treatment is terbinafine, with a dosing regimen of 250 mg daily for 6 weeks (fingernails) or 12 weeks (toenails), achieving 70-80% cure rates for toenails and 80-90% for fingernails, according to the British Journal of Dermatology 1, 3
The American Academy of Dermatology supports the use of itraconazole as a second-line treatment for dermatophyte onychomycosis, with dosing options of either 200 mg daily for 12 weeks continuously or pulse therapy 400 mg daily for 1 week per month, with clinical cure rates of 14-26% and mycological cure of 54% 1, 3, 4
For candida onychomycosis, the first-line treatment is itraconazole, with a dosing regimen of 200 mg daily or pulse therapy 400 mg daily for 1 week per month, due to its shorter treatment duration and cost-effectiveness, as recommended by the Infectious Diseases Society of America 1, 7, 8

In diabetic patients, terbinafine is preferred over itraconazole due to its lower risk of drug interactions and no hypoglycemia risk, with the American Diabetes Association recommending careful consideration of treatment options in this population 6, 9, 10
In pediatric patients, both terbinafine and itraconazole are first-line options, with higher cure rates than in adults, and the American Academy of Pediatrics recommending weight-based dosing for terbinafine and pulse therapy for itraconazole 2, 6, 9, 10

Topical agents are inferior to systemic therapy except for very distal infection or superficial white onychomycosis, with the American Academy of Dermatology recommending their use as an adjunct to systemic therapy for improved cure rates 1, 3
Amorolfine 5% lacquer and ciclopirox 8% lacquer are topical options, with application regimens of once or twice weekly for 6-12 months and daily for up to 48 weeks, respectively, as recommended by the European Academy of Dermatology and Venereology 3

The British Journal of Dermatology emphasizes the importance of obtaining mycological confirmation before initiating treatment, with a minimum follow-up period of 48 weeks from treatment start, to allow identification of superior drug and detection of relapse 1, 5
Regular antifungal powder application inside shoes and periodic terbinafine solution spraying into shoes are recommended for prevention of recurrence, with a 25% relapse rate, as suggested by the Infectious Diseases Society of America 5

Starting treatment without mycological confirmation leads to unnecessary therapy for non-fungal nail dystrophies, with the American Academy of Dermatology recommending careful diagnosis and treatment planning 1, 7
Inadequate treatment duration results in higher relapse rates, with the European Academy of Dermatology and Venereology recommending completion of the full treatment course 1
Ignoring drug interactions, particularly itraconazole with statins, antiretrovirals, and in heart failure patients, is a common pitfall, with the American Heart Association recommending careful consideration of treatment options in this population 6, 3, 5